Clinical Trial Update: An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) [Phase 3]

View source ↗

Summary

An extension study to evaluate the long-term safety of subcutaneous tocilizumab in participants with giant cell arteritis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Giant Cell Arteritis | Phase 3 | Status: COMPLETED